Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Next stop- multiple license agreements - regionalized for B-OM
Also, Breakthrough designation.
You will see that. Not a RS
Really good info! Thanks
Bahaaaa! Probability of success in phase 2 is 30.7%. Once you get to phase 3 it is almost 60%.
Double bun.
Keep spreading lies and FUD.
https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf
Page 7. - overall rates
Have it hit .26 for all I care. I know what’s coming. Multiple partnerships and billions of revenue. All coming soon - very soon!
My kaboom was to shut all yous up who are crying that data is bad and Leo is hiding. Bahahaaaaaa. Again lies upon lies.
Boom!!!!! Everyone R-E-L-A-X!
Leo will PR it. Look at my time comparison to phase 2a. We are 5 days short of that trial and that trial only had 9 sites to collect and coordinate. We have 34 this time and had Christmas and new year in this time frame. No way we beat phase 2a time frame. Add 4 weeks imo.
Great question :)
No news, there can be no P leaks as data is not unblinded.
Maybe BP trying to show muscle and pit it’s heal on Leo’s throat?
Well bad news for them.......there are a dozen others interested. Haha!!!
Get ready for a run like no other. .60 to 1.80 to 5.40 to 16 to 28 to 45 to 74 to 101. All within 2 years. Let’s roll Leo
How does the Bid and Ask become One??? Lol. I guess I’ll Bid .64 all while hitting the ask. Ha
Lol. Nooooo you think?!?! We prob close green
Booyaaaaa!!! Congrats. For real. B-OM alone with one employee is worth double the current MC.
It’s national margarita day...I suggest logging off and enjoying one ;)
Lol. Excellent! Thank you.
As I’ve said. I have an elderly friend who is a Harvard grad and multi multi millionaire investor truly excited about Prurisol and just threw down 100K for these results.
I’m not even a decimal of this guys intelligence and life experience. So when I hear excitement from someone like this....it makes me feel better...lol
I’m sorry for you Sir. Spreading unknown lies that IPIX has the data and are trying to figure out how to let shareholders know P phase 2b was a flop?????
First of all. Leo and team have always been upfront and tell shareholders almost too much any Telegraph too much imo. They cannot hold out data from shareholders for starters. So your theory is bunk.
Second. Again!!!! Phase 2a completed the last patient visit on March 17th 2016.
They PRd that they expected the BLIND to be removed next week on May 11th and telegraphed their expectation to be able to digest and release the data one week after that. So approx 2 weeks from May 11th
May 24ththe topline was PRd.
So——- phase 2a ——115 patients
Approx 9 sites to collect data from
69 days to deliver data from last patient visit.....
PHASE2b
199 patients. 73% more patients
34 study sites 270% more sites
Final patient visit ——December 21
Today is 2.21 —- 63 days have passed
We are under by 6 days for one!!! And two, we have 270% more sites to collect data from and 73% more patients.
I’d expect data late March if nothing snags. IMO.
They do not have data. And they most likely will PR when the data is unblinded just like before.
Bahahaaa. The phase 2a was much smaller with a fraction of sites to close and collect data. The patient population was much smaller and it took just about this much time. I’d expect another couple weeks. It may even push into April if there are snags. Come on man. Get real
I know you are for the buyout. I’m for license for each. I’m not young but not old. I’d like to wait another 10 years for full maturity. Maybe 2025 and each are bringing in multi billions.
Prurisol could potentially be a huge easy sale for billions if it hit 50% + PASI 75. 5-6 billion Is think 30% could garner billion plus. Today.
The safety. The patents. The fully owned IP, the ease of manufacturing and cost, the 505 2b destination adding additional years of exclusivity. All of that would equal an enormous cash deal imo.
I’m super excited. We will all know soon. If it flops. We have B and K ;)
The scenarios are countless. Honestly
Interesting. However, I think the curve from 100mg to 200mg was observed and very positive. So imo the curve from 200 to 300 could be more significant and we will not know until results are shown. Your other statement about mild and moderate compared to moderate and severe will also be positive for IPIX.
Anyway, thanks for the data.
I think K has the majority. Jmo
Have you studied the pre clinical P data? Those mice pix are pretty amazing. I also think P will transform this company. I’ve said it a couple times before. I know a sharp that put 100K into this company in the past 3 months just for P results.
I’m ready for some results. Any day now...
IMO. The types of PRs and the feeling around the company, IPIX is in deep negotiations with several BP. They have many more CDAs but I think there is major discussions with a handful. Tensions are high and I expect a deal this year.
Good luck my friends. I will buy more when I get my tax return. Under 10 bucks
Prurisol topline data is scheduled to be released in Q-1. We have about 40 days. Give or take.
Prurisol is IPIX’s dark horse drug. There are no expectations set. They went at in phase 2a and saw a dose related improvement so they raised the dose up a notch twice. 200 to 300 and 400.
Pre clinical showed huge efficacy. Almost a cure.
We all - short or long will find out if Prurisol can compete with Otezla soon
Back to work today? Welcome back
Agree. I don’t think they will disclose info leading up to final decision. I think the 20 CDA is all we get. It was a good move to tell us shareholders it was approaching 20 and not just 3-5 .....
Huge difference. A CDA is not everyday stuff.
I actually think we either get K data from oral testing that concluded late 17 or we get Prurisol data.
Prurisol data if better than Otezla could mean a lot to IPIX at this juncture. It adds another iron to a blazing fire. Those things make trigger happy moves.
I hope we see above 40% PASI 75.
That would warrant ATLEAST a billion market cap for starters imo.
200 mg was significant. Now let’s see double that with severe psoriasis. I say we get good results. If nerby post was not BS....we are in for a treat and should finally get this company moving.
Also, if P results are dominant it makes the other indications that much more desirable and valuable. IMO.
I think we get notice. Unless Leo wants to be sneaky. Drops a score of 58% PASI 75 out of the blue would be great. ;)
I believe IPIX has an agreement already signed with a major BP. The minute B is on the market, the agreement can go through. I can’t find the PR right now. It was several years ago.
Really good post. I missed this. Thanks.
SS - When has the company lied or misled us? In my 6-7 years...never. I look at companies every day and do DD - I get to know the PR style and the MGMT style... In my most honest opinion you will not find a better MGMT team than at IPIX. They truly care. They want the best for their shareholders.
They could have gone several different ways - RS - Uplist - etc... However they have a plan and sticking to it. The value that these drugs could possibly bring to market are extreme - imo they have 3 blockbusters on hand and have not failed a trial.
Lets REVISIT:
___________________________________________________
BEVERLY, MA – January 29, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
· The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
· A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
· After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
· “Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
· http://www.ipharminc.com/brilacidin-1/
__________________________________________________________
That is in fact alot going on for a SMALL BIOTECH. Not to mention unblinding Prurisol data alone and attempting to make the first ever safe P53 drug into ORAL!
This board is toxic and again has spun-up FEAR and LIES.
We can't stop it and Leo knows that. But for all the true investors, just know that this board is the furthest from the truth and what is really going on with the company. They are hard at work every day --- entertaining many questions and possible offers and giving more and more detail to their pipeline to BP and BIO's all while running a business and moving forward. It is not a small task to do so.
As KarinCA suggested - watching IPIX over the years, to let go workers is on par. Dr. J - gone - when done with getting B thru phase 2b. One example. All Trials are currently done! ALL TRIALS ARE CURRENTLY DONE! So there is no need for many right now. If I was a betting man...I'd say we are about to partner and use another companies resources for the rest of the way. JMO
Reread the PRs over the past year. Everything is on target. Anchoring was first discussed in Karin’s interview with Dr B years ago. What has happened and come true???? They have anchored the Brilacidin franchise. PERIOD! And FACT!
Final data - submission for breakthrough is underway.
IPIX is the CLEAR leader in OM per the scientific community. A deal is being worked and it will break all the shackles that have been imaginary
I just stated my knowledge. The patents, the equipment and the drugs could all go for over a billion dollars in a snap. There is zero intention to sell or partner for under value. Leo will maximize value and that is a fact.
Agree. This board has spun a story and is now so far from the truth. The fact is...the company is stronger than ever. There is not one ounce of nervousness or doubt within the Beverly building. I know that for a fact.
Just....I see you on a board of another Co I’m looking into. Unreal just a few days ago that market cap was up in the 80 million and they have zero trials in the clinic and they are on the Nasdaq. They have great news ... clay comes to board and boom a 26% down day.
I’ll tell you. Bio is not for the weak.
IPIX should easily be in the 500 million to 1. Billion Mc today. EASILY.
IPIX WILL INK ITS FIRST PARTNER THIS YEAR. MAYBE THIS FIRST HALF OF YEAR.
Commercials for Otezla and Taltz back to back on good morning America....psoriasis is a hot market and a newer safer and mor efficacious drug will warrant billions imo.
Cash is needed! To make our jump. OR........Prurisol racks in like 40% PASI 75 in a 12 week time frame. Now that would warrant huge gains..but cash would be needed shortly after.
I read the PR as we are approaching 20 CDAs. Meaning a BP or Bio signs a CDA - that CDA is good for one drug or all drugs. That’s my take
I think he meant he was in it for 3 years and flat. For a long time....so when you see it double, he pulled the trigger even though he initially believed in a much higher price. He lost patience...and then lost out on 700% more
It’s not happening to me here. I believe this is a triple digit stock. I may take off a few thousand shares in the 20’s but then will wait for triple digits.
Great insight. Real numbers.
Marked. I can’t wait for a >40% PASI 75. It costs how much for a pill to be manufactured? The margins are going to be nutzzzzzzzz!!!!!!
Right and you are clueless to what BP thinks P, K and B are worth. You will find out soon enough on ATLEAST one of them.....stay tuned homie.
BAD example. Kevetrin and Prurisol trumped their pipeline by many billions.
Imo
You all will lose on this stock by bashing it. Period.
I said I agree to NO FULL BUYOUT. No way! A sale of one drug? Absolutely if the price is right. Let’s discuss Prurisol. The trial design for phase 2b is an apples to apples view against the blockbuster oral drug Otezla. Otezla set the bar at 30-33% PASI 75.
That’s simple to compare.
I know Georgjii says Prurisol may help other indications as does the company, but as of now it’s the dark horse drug candidate.
If I ran the company and knew B and Ks possible value and believed P to be a drug for just P psoriasis I would for sure sell if results were great.
I believe the Oral psoriasis market is extremely valuable today and anything over 30% PASI 75 would garner a multi billion sale of said drug.
Remember; it has the 505 2b designation that will allow a cheaper phase 3 and also offer a possibility to a 3-5 year exclusivity extension (huge) and P is cheap to manufacturer and also extremely safe and not to mention is fully owned by IPIX - no profit sharing. All of that makes the drug extremely easy to sell outright for a premium imo.
So let’s say they hit 50% PASI 75 - ummm. Boom! Many Billion buyout easy. If it’s Georgjii style results 10 Billion buyout easy of drug.
But to sell the entire company right now. IMO. Hahaha. No way.